The increasing demand for objective, neurophysiological tools to assess brain function in clinical settings has led to the development of advanced technologies, such as the BrainView qEEG discriminant database by Medeia Inc. The BrainView system provides a comprehensive approach to understanding cognitive processing changes due to aging and pathological conditions. This platform leverages key biomarkers like the N100, P300, and N400 event- related potentials (ERPs) to identify electrophysiological abnormalities and offer insights into cognitive processing across aging and neurological disorders. Age-related cognitive decline is often marked by alterations in these ERP components, particularly in attention, memory, and semantic processing. However, ERP alterations are more severe in pathological aging and disease. Additionally, these ERPs have proven essential in understanding conditions such as traumatic brain injury (TBI), schizophrenia, autism spectrum disorder (ASD), stroke, Alzheimer's disease (AD), and others. The BrainView system’s ability to detect subtle changes in brain function makes it a critical tool for early diagnosis, monitoring disease progression, and evaluating therapeutic interventions. With its extensive dataset, advanced statistical methods, and clinical focus, BrainView aids clinicians in making more informed decisions regarding patient care. As the database expands to include additional disorders, its role in personalized medicine and improving patient outcomes is set to grow. The BrainView ERP Platform represents a transformative advancement in neurophysiology and neuropsychology, offering a comprehensive, efficient, and accurate solution for brain health assessments, ultimately paving the way for a new standard in clinical neuroassessment.